Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis

[1]  K. Chayama,et al.  Impact of sclerosing dacryoadenitis/sialadenitis on relapse during steroid therapy in patients with type 1 autoimmune pancreatitis , 2019, Scandinavian journal of gastroenterology.

[2]  M. Ota,et al.  Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis , 2018, Scientific Reports.

[3]  N. Tanaka,et al.  Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease , 2018, World journal of gastroenterology.

[4]  B. Petersen,et al.  Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4‐related Disease , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  M. Ota,et al.  Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  Naoyuki Fujimori,et al.  Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C , 2017, Scientific Reports.

[7]  S. Chari,et al.  Azathioprine Maintenance Therapy to Prevent Relapses in Autoimmune Pancreatitis , 2017, Clinical and Translational Gastroenterology.

[8]  Jiujie Cui,et al.  The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[9]  Y. Hirooka,et al.  Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients , 2017, Journal of Gastroenterology.

[10]  K. Uchida,et al.  Long-term outcomes of autoimmune pancreatitis , 2016, World journal of gastroenterology.

[11]  H. Sugimoto,et al.  Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis , 2016, Gut.

[12]  K. Uchida,et al.  Autoimmune Pancreatitis: The Past, Present, and Future. , 2015, Pancreas.

[13]  D. Brindley,et al.  Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate[S] , 2015, Journal of Lipid Research.

[14]  I. Tsuji,et al.  Nationwide Epidemiological Survey of Autoimmune Pancreatitis in Japan in 2011 , 2015, Pancreas.

[15]  J. Stone,et al.  IgG4-related disease. , 2014, Annual review of pathology.

[16]  T. Shimosegawa,et al.  Recent Advances in the Diagnosis and Management of Autoimmune Pancreatitis: Similarities and Differences in Japan and Korea , 2013, Gut and liver.

[17]  K. Momma,et al.  Clinical Characteristics of Patients with Autoimmune Pancreatitis with or without Mikulicz's Disease and Mikulicz's Disease Alone , 2012, Gut and liver.

[18]  Michael J Levy,et al.  Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience , 2012, Gut.

[19]  S. Kuriyama,et al.  Nationwide Epidemiological Survey of Autoimmune Pancreatitis in Japan , 2012, Pancreas.

[20]  K. Tsubota,et al.  A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details , 2011, Modern rheumatology.

[21]  Hisanori UmeharaKazuichi.  A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details , 2012 .

[22]  K. Uchida,et al.  Recent Concepts of Autoimmune Pancreatitis and IgG4-Related Disease , 2011, Clinical reviews in allergy & immunology.

[23]  Anastassis Perrakis,et al.  Insights into autotaxin: how to produce and present a lipid mediator , 2011, Nature Reviews Molecular Cell Biology.

[24]  N. Sasahira,et al.  Specific increase in serum autotaxin activity in patients with pancreatic cancer. , 2011, Clinical Biochemistry.

[25]  Myung-Hwan Kim,et al.  International Consensus Diagnostic Criteria for Autoimmune Pancreatitis: Guidelines of the International Association of Pancreatology , 2011, Pancreas.

[26]  M. Kurokawa,et al.  Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma , 2008, British journal of haematology.

[27]  Julie Klein,et al.  Lysophosphatidic acid and renal fibrosis. , 2008, Biochimica et biophysica acta.

[28]  B. Petersen,et al.  Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. , 2008, Gastroenterology.

[29]  J. Wain,et al.  The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak , 2008, Nature Medicine.

[30]  H. Inoko,et al.  Two critical genes (HLA-DRB1 and ABCF1)in the HLA region are associated with the susceptibility to autoimmune pancreatitis , 2006, Immunogenetics.

[31]  T. Kamisawa,et al.  Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease , 2006, Journal of Gastroenterology.

[32]  K. Shiratori,et al.  Chronic pancreatitis caused by an autoimmune abnormality , 1995, Digestive Diseases and Sciences.

[33]  T. Smyrk,et al.  Controversies in Clinical Pancreatology: Autoimmune Pancreatitis: Does It Exist? , 2003, Pancreas.

[34]  T. Nikaido,et al.  High serum IgG4 concentrations in patients with sclerosing pancreatitis. , 2001, The New England journal of medicine.

[35]  L. Liotta,et al.  Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. , 1992, The Journal of biological chemistry.